Inogen (NASDAQ:INGN – Get Free Report) and PAVmed (NASDAQ:PAVM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.
Earnings & Valuation
This table compares Inogen and PAVmed”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inogen | $348.67 million | 0.50 | -$22.75 million | ($0.91) | -7.04 |
| PAVmed | $70,000.00 | 73.71 | $400,000.00 | ($37.40) | -0.14 |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Inogen and PAVmed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inogen | 1 | 0 | 0 | 1 | 2.50 |
| PAVmed | 1 | 1 | 1 | 0 | 2.00 |
PAVmed has a consensus target price of $56.00, indicating a potential upside of 985.27%. Given PAVmed’s higher possible upside, analysts clearly believe PAVmed is more favorable than Inogen.
Volatility & Risk
Inogen has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Profitability
This table compares Inogen and PAVmed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inogen | -7.08% | -12.90% | -8.27% |
| PAVmed | -21,914.12% | -146.19% | -18.39% |
Institutional and Insider Ownership
89.9% of Inogen shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 2.5% of Inogen shares are held by insiders. Comparatively, 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Inogen beats PAVmed on 9 of the 15 factors compared between the two stocks.
About Inogen
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
About PAVmed
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.
